A hearing in the U.S. House of Representatives dealing with FDA regulation of commercial speech highlighted the partisan nature of this issue, but the Republican majority in the House and the FDA's inability to come to terms with the First Amendment suggest that support for the two bills in question will continue to build, particularly given that patient advocates at the hearing had few kind words for the legal and regulatory status quo.